SPDP-PEG4-NHS ester is a PEG Linker.

SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker u

PEG4-SPDP is a cleavable ADC linker used for the antibody-drug conjugates (ADCs).

VcMMAE is an antibody-drug conjugate (ADC) with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker.

Amino-PEG8-Azido is a non-cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Maytansinoid DM4, a chemical derivative of maytansine, is a potent and selective cytotoxic agent with promising anticancer properties. Anticancer properties of maytansinoids have been attributed to their ability to disrupt microtubule function. Maytansin

TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.

TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer.

Val-Ala-PAB-SN38 TFA is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB and SN38, which is the active metabolite of the Topoisomerase I inhibitor Irinotecan

Mal-PEG8-Val-Cit-Exatecan (Compound 1033) is a Drug-Linker Conjugates for ADC, which is composed of Exatecan and a linker. Mal-PEG8-Val-Cit-Exatecan can be used for ADC synthesis.

Fmoc-Val-Lys(Boc)-PAB-Exatecan (Compound 39-7) is a Drug-Linker Conjugates for ADC. Fmoc-Val-Lys(Boc)-PAB-Exatecan consists of the ADC Cytotoxin Exatecan and a linker PAB-Val-Lys-Boc. Fmoc-Val-Lys(Boc)-PAB-Exatecan can be used for synthesis of ADCs.

DBCO-PEG8-VKG-CPT2 is a drug-linker conjugate for ADC. DBCO-PEG8-VKG-CPT2 consists of a topoisomerase 1 inhibitor (7-MAD-MDCPT) and a stable and cleavable linker (DBCO-PEG8-VKG). DBCO-PEG8-VKG-CPT2 can be used for synthesis of ADCs.

DBCO-HS-PEG2-VA-PABC-SG3199 is a drug-linker conjugate for ADC. DBCO-HS-PEG2-VA-PABC-SG3199 consists of a SG3199) based DNA small channel crosslinker and cleavable linker. DBCO-HS-PEG2-VA-PABC-SG3199 can be used for synthesis of ADCs.

DBCO-PEG4-VA-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG4-VA-PABC-MMAE consists of a tubulin inhibitor (MMAE) and a cleavable linker (DBCO-PEG4-VA-PABC). DBCO-PEG4-VA-PABC-MMAE can be used for synthesis of ADC ABBV-400.

RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide is a drug-linker conjugate for ADC. RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide consists of a GPX4 inhibitor and ferroptosis inducer (RSL3-NH2) and a linker (H-Ala-Val-OH). RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide can be used for synthesis of ADCs.

DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable DBCO-PEG3-Glu-VC-PABC. DBCO-PEG3-Glu-VC-PABC-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).

LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab by WT Endo-S2.

MCC-AAQ-Exa is a drug-linker conjugates for ADC, obtained by condensing the linker with Exatecan and can be used to prepare antibody-drug conjugates (ADCs). MCC is an ADC linker containing a maleimide fragment.

APL-1082 (exo-EVC-Exatecan) is a drug-Linker conjugate that can be used for ADC synthesis. Its structure contains Exatecan (ADC payload) and linker.

LM-D01 is a Drug-Linker Conjugates for ADC. LM-D01 consists of the ADC Cytotoxin Exatecan-3-amine178265) and a linker MC-GGFG-NH-CH2-O-propionic acid. LM-D01 can be used for synthesis of ADCs.

JSSW-001 is a drug-linker compound applicable for the preparation of antibody-drug conjugates (ADCs). JSSW-001 can be used for the study of cancer.

LD-38 is a drug-linker conjugate for ADC. LD-38 consists of a topoisomerase 1 inhibitor (Exatecan) and a highly hydrophilic stable and cleavable linker. LD-38 can be used for synthesis of ADC.

Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan(topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis.

Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a drug-linker conjugate for ADC. Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide consists of a Triptolide and a stable and cleavable linker (Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-Cl). Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide can be used for synthesis of antibody-drug conjugates (ADC).

GDP-Fuc-AM-VcPAB-MMAE is a conjugate of toxic molecules and linkers. GDP-Fuc-AM-VcPAB-MMAE is an important precursor molecule that can be used to prepare ADC drugs. GDP-Fuc-AM-VcPAB-MMAE can be used for cancer research.

Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC, which is composed of a linker Boc-Val-Cit-PAB (HY141141) and a Microtubule inhibitor MMAE. Boc-Val-Cit-PAB-MMAE can be used for ADC synthesis.

Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs.

Mal-Val-Lys-PAB-MMAE is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE consists of a Tubulin inhibitor (MMAE) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE can be used for synthesis of ADCs.

Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan(topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis.